C

Chatham-Kent Clinical Trials Research Centre | Chatham, Canada

Research site

(Unclaimed)

Location

240 Grand Ave W Suite #214, Chatham, Ontario, Canada

Site insights

Top conditions

Top treatments

BI 409306

PF-05212377

Troriluzole

Methylphenidate Hydrochloride

SEP-363856

Troriluzule

Lisdexamfetamine Dimesylate

BI 425809

Donepezil

Vortioxetine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 12 total trials

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting

Major Depressive Disorder

Other: Placebo

Drug: SEP-363856

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Active, not recruiting

Obsessive-Compulsive Disorder

Drug: Troriluzole

Drug: Placebo

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)